79762-54-2 Usage
Description
6-Bromoindazole, also known as 6-Bromo-1H-indazole, is an indazole derivative that has been extensively studied for its potential as an inhibitor of DNA gyrase B and its antibacterial activity. It is a promising compound in the field of pharmaceuticals and microbiology due to its unique chemical structure and properties.
Uses
Used in Pharmaceutical Industry:
6-Bromoindazole is used as an inhibitor of DNA gyrase B for its antibacterial activity. It targets the enzyme DNA gyrase B, which is essential for bacterial DNA replication, transcription, repair, and recombination. By inhibiting this enzyme, 6-Bromoindazole can effectively disrupt the bacterial cell's ability to replicate its DNA, leading to the inhibition of bacterial growth and potentially killing the bacteria.
Furthermore, 6-Bromoindazole is being studied for its potential use in treating bacterial infections caused by antibiotic-resistant strains. Its unique mechanism of action and ability to target DNA gyrase B make it a promising candidate for the development of new antibiotics to combat drug-resistant bacteria.
In addition to its antibacterial properties, 6-Bromoindazole is also being investigated for its potential applications in other areas of pharmaceutical research. Its ability to modulate various biological processes and interact with different molecular targets makes it a versatile compound with potential applications in various therapeutic areas, such as anti-inflammatory, antifungal, and anticancer treatments.
Overall, 6-Bromoindazole is a promising indazole derivative with a wide range of potential applications in the pharmaceutical industry, particularly in the development of new antibiotics to combat antibiotic-resistant bacteria and the exploration of its potential in other therapeutic areas.
Check Digit Verification of cas no
The CAS Registry Mumber 79762-54-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,9,7,6 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 79762-54:
(7*7)+(6*9)+(5*7)+(4*6)+(3*2)+(2*5)+(1*4)=182
182 % 10 = 2
So 79762-54-2 is a valid CAS Registry Number.
79762-54-2Relevant articles and documents
Compound with AMPK agonistic activity and preparation and application of prodrug thereof
-
Paragraph 0359-0362, (2021/10/27)
The invention relates to a compound with AMPK agonistic activity and a prodrug thereof, and as well as a preparation method and medical application of a prodrug thereof. The compound has the structure shown in the formula (I), and the prodrug of the compound has the structure shown in the formula (II), wherein each group and the substituent are as defined in the specification. The invention discloses a preparation method of the compound and application of the compound in prevention and treatment AMPK related diseases, and the AMPK related diseases include, but are not limited to, energy metabolism abnormality related diseases. Neurodegenerative diseases and inflammation-related diseases and the like.
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00453, (2020/06/19)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Yao, Xia,Sun, Xiuyun,Jin, Shuyu,Yang, Ling,Xu, Hongjiang,Rao, Yu
, p. 6561 - 6574 (2019/08/20)
A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.
